A protein called PIKfyve impacts multiple processes involved in metabolism and cell death; blocking it is key to making immunotherapy work in prostate cancer.
An analysis of patient data from across Michigan found scores from the Decipher Biopsy test independently aligned with outcomes.
Known as HIPEC, the therapy has been available for adults for years at Michigan Medicine. Now it’s an option for kids here, too.
Among those who underwent a mastectomy and breast reconstruction, there were no significant differences in complication rate or patient well-being for women who received chemotherapy as an additional treatment compared to those who did not.
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not.
The effort by the Michigan Radiation Oncology Quality Consortium reduced unnecessary medical procedures, and saved the time and resources of patients and families.